Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Passage Bio, Inc. (PASG) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Passage Bio, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1787297.
Total stock buying since 2020: $46,615,760.
Total stock sales since 2020: $1,685,497.
Total stock option exercises since 2020: $97,254.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 128,848 | $733,852 | 1,341,709 | $572,881 | 8,000 | $0 |
| 2024 | 829,998 | $525,573 | 444,216 | $345,457 | 9,000 | $0 |
| 2023 | 1,192,577 | $1,001,763 | 17,558 | $16,013 | 180,000 | $0 |
| 2022 | 1,222,400 | $4,794,592 | 5,401 | $7,486 | 17,500 | $0 |
| 2021 | 2,000 | $26,230 | 27,598 | $743,660 | 81,975 | $97,254 |
| 2020 | 2,198,000 | $39,533,750 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-07 | 128,848 | $733,852 | 0 | $0 | 0 | $0 |
| 2025-06 | 0 | $0 | 583,657 | $197,238 | 0 | $0 |
| 2025-04 | 0 | $0 | 384,626 | $128,431 | 0 | $0 |
| 2025-02 | 0 | $0 | 3,183 | $1,686 | 8,000 | $0 |
| 2025-01 | 0 | $0 | 370,243 | $245,526 | 0 | $0 |
| 2024-12 | 373,645 | $241,001 | 159,379 | $129,326 | 0 | $0 |
| 2024-11 | 456,353 | $284,572 | 0 | $0 | 0 | $0 |
| 2024-09 | 0 | $0 | 239,431 | $174,629 | 0 | $0 |
| 2024-02 | 0 | $0 | 3,108 | $3,013 | 9,000 | $0 |
| 2024-01 | 0 | $0 | 42,298 | $38,489 | 0 | $0 |
| 2023-12 | 0 | $0 | 0 | $0 | 130,000 | $0 |
| 2023-07 | 0 | $0 | 11,453 | $10,078 | 31,250 | $0 |
| 2023-06 | 1,192,577 | $1,001,763 | 4,052 | $3,780 | 12,500 | $0 |
| 2023-04 | 0 | $0 | 2,053 | $2,155 | 6,250 | $0 |
| 2022-11 | 0 | $0 | 3,720 | $4,947 | 12,500 | $0 |
| 2022-09 | 0 | $0 | 1,681 | $2,539 | 5,000 | $0 |
| 2022-05 | 525,000 | $1,016,285 | 0 | $0 | 0 | $0 |
| 2022-03 | 10,000 | $31,500 | 0 | $0 | 0 | $0 |
| 2022-01 | 687,400 | $3,746,807 | 0 | $0 | 0 | $0 |
| 2021-12 | 0 | $0 | 0 | $0 | 71,975 | $16,554 |
| 2021-05 | 2,000 | $26,230 | 0 | $0 | 0 | $0 |
| 2021-03 | 0 | $0 | 10,000 | $214,080 | 10,000 | $80,700 |
| 2021-01 | 0 | $0 | 17,598 | $529,580 | 0 | $0 |
| 2020-03 | 1,824,700 | $32,814,350 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-24 | Nichols Weston | Buy | 66,423 | 5.71 | 379,474 |
| 2025-07-23 | Nichols Weston | Buy | 49,302 | 5.74 | 283,042 |
| 2025-07-22 | Nichols Weston | Buy | 13,123 | 5.44 | 71,336 |
| 2025-06-26 | Orbimed Capital Gp Vii Llc | Sale | 213,257 | .33 | 70,374 |
| 2025-06-25 | Orbimed Capital Gp Vii Llc | Sale | 138,800 | .33 | 45,804 |
| 2025-06-24 | Orbimed Capital Gp Vii Llc | Sale | 231,600 | .35 | 81,060 |
| 2025-04-24 | Orbimed Capital Gp Vii Llc | Sale | 68,195 | .32 | 21,822 |
| 2025-04-23 | Orbimed Capital Gp Vii Llc | Sale | 89,328 | .34 | 30,371 |
| 2025-04-22 | Orbimed Capital Gp Vii Llc | Sale | 78,049 | .34 | 26,536 |
| 2025-04-17 | Orbimed Capital Gp Vii Llc | Sale | 77,090 | .33 | 25,439 |
| 2025-04-16 | Orbimed Capital Gp Vii Llc | Sale | 61,638 | .33 | 20,340 |
| 2025-04-15 | Orbimed Capital Gp Vii Llc | Sale | 10,326 | .38 | 3,923 |
| 2025-02-11 | Borthwick Kathleen (CFO) | Sale | 3,183 | .53 | 1,686 |
| 2025-02-10 | Borthwick Kathleen (CFO) | Option Ex | 8,000 | .00 | 0 |
| 2025-01-14 | Orbimed Capital Gp Vii Llc | Sale | 79,024 | .60 | 47,414 |
| 2025-01-13 | Orbimed Capital Gp Vii Llc | Sale | 17,986 | .64 | 11,511 |
| 2025-01-10 | Orbimed Capital Gp Vii Llc | Sale | 126,209 | .66 | 83,297 |
| 2025-01-08 | Orbimed Capital Gp Vii Llc | Sale | 75,007 | .68 | 51,004 |
| 2025-01-07 | Orbimed Capital Gp Vii Llc | Sale | 52,536 | .71 | 37,300 |
| 2025-01-06 | Orbimed Capital Gp Vii Llc | Sale | 19,481 | .77 | 15,000 |
| 2024-12-27 | Nichols Weston | Buy | 373,645 | .65 | 241,001 |
| 2024-12-11 | Orbimed Capital Gp Vii Llc | Sale | 80 | .80 | 64 |
| 2024-12-10 | Orbimed Capital Gp Vii Llc | Sale | 8,015 | .80 | 6,412 |
| 2024-12-09 | Orbimed Capital Gp Vii Llc | Sale | 54,181 | .84 | 45,512 |
| 2024-12-06 | Orbimed Capital Gp Vii Llc | Sale | 20,903 | .82 | 17,140 |
| 2024-12-04 | Orbimed Capital Gp Vii Llc | Sale | 76,200 | .79 | 60,198 |
| 2024-11-27 | Nichols Weston | Buy | 29,300 | .67 | 19,660 |
| 2024-11-26 | Nichols Weston | Buy | 167,055 | .71 | 118,274 |
| 2024-11-25 | Nichols Weston | Buy | 259,998 | .56 | 146,638 |
| 2024-09-19 | Orbimed Capital Gp Vii Llc | Sale | 39,300 | .71 | 27,903 |
| 2024-09-18 | Orbimed Capital Gp Vii Llc | Sale | 25,631 | .73 | 18,710 |
| 2024-09-17 | Orbimed Capital Gp Vii Llc | Sale | 111,400 | .73 | 81,322 |
| 2024-09-16 | Orbimed Capital Gp Vii Llc | Sale | 63,100 | .74 | 46,694 |
| 2024-02-13 | Borthwick Kathleen (SVP, INTERIM CFO) | Sale | 1,470 | .97 | 1,425 |
| 2024-02-13 | Forman Mark S (CHIEF MEDICAL OFFICER) | Sale | 1,638 | .97 | 1,588 |
| 2024-02-10 | Borthwick Kathleen (SVP, INTERIM CFO) | Option Ex | 4,000 | .00 | 0 |
| 2024-02-10 | Forman Mark S (CHIEF MEDICAL OFFICER) | Option Ex | 5,000 | .00 | 0 |
| 2024-01-02 | Borthwick Kathleen (SVP, Interim CFO) | Sale | 10,672 | .91 | 9,711 |
| 2024-01-02 | Forman Mark S (Chief Medical Officer) | Sale | 15,813 | .91 | 14,389 |
| 2024-01-02 | Cale Edgar B. (GC & Corporate Secretary) | Sale | 15,813 | .91 | 14,389 |
| 2023-12-31 | Borthwick Kathleen (SVP, Interim CFO) | Option Ex | 30,000 | .00 | 0 |
| 2023-12-31 | Forman Mark S (Chief Medical Officer) | Option Ex | 50,000 | .00 | 0 |
| 2023-12-31 | Cale Edgar B. (GC & Corporate Secretary) | Option Ex | 50,000 | .00 | 0 |
| 2023-07-28 | King Simona (Chief Financial Officer) | Sale | 11,453 | .88 | 10,078 |
| 2023-07-28 | King Simona (Chief Financial Officer) | Option Ex | 31,250 | .00 | 0 |
| 2023-06-28 | Orbimed Capital Gp Vii Llc | Buy | 575,195 | .84 | 483,163 |
| 2023-06-27 | Orbimed Capital Gp Vii Llc | Buy | 617,382 | .84 | 518,600 |
| 2023-06-16 | Fotopoulos Alexandros (Chief Technical Officer) | Sale | 4,052 | .93 | 3,780 |
| 2023-06-15 | Fotopoulos Alexandros (Chief Technical Officer) | Option Ex | 12,500 | .00 | 0 |
| 2023-04-18 | King Simona (Chief Financial Officer) | Sale | 2,053 | 1.05 | 2,155 |
| 2023-04-18 | King Simona (Chief Financial Officer) | Option Ex | 6,250 | .00 | 0 |
| 2022-11-22 | Fotopoulos Alexandros (Chief Technical Officer) | Sale | 3,720 | 1.33 | 4,947 |
| 2022-11-22 | Fotopoulos Alexandros (Chief Technical Officer) | Option Ex | 12,500 | .00 | 0 |
| 2022-09-19 | Toernsen Monika Maria (Chief Commercial Officer) | Sale | 1,681 | 1.51 | 2,539 |
| 2022-09-15 | Toernsen Monika Maria (Chief Commercial Officer) | Option Ex | 5,000 | .00 | 0 |
| 2022-05-04 | Orbimed Capital Gp Vii Llc | Buy | 303,500 | 1.94 | 588,790 |
| 2022-05-03 | Orbimed Capital Gp Vii Llc | Buy | 221,500 | 1.93 | 427,495 |
| 2022-03-21 | Goldsmith Bruce A (CEO and President) | Buy | 10,000 | 3.15 | 31,500 |
| 2022-01-20 | Orbimed Capital Gp Vii Llc | Buy | 369,100 | 5.42 | 2,000,522 |
| 2022-01-19 | Orbimed Capital Gp Vii Llc | Buy | 43,300 | 5.11 | 221,263 |
| 2022-01-18 | Orbimed Capital Gp Vii Llc | Buy | 114,700 | 5.46 | 626,262 |
| 2022-01-14 | Orbimed Capital Gp Vii Llc | Buy | 10,300 | 5.60 | 57,679 |
| 2022-01-13 | Orbimed Capital Gp Vii Llc | Buy | 41,800 | 5.52 | 230,735 |
| 2022-01-12 | Orbimed Capital Gp Vii Llc | Buy | 100,000 | 5.65 | 565,000 |
| 2022-01-11 | Orbimed Capital Gp Vii Llc | Buy | 8,200 | 5.53 | 45,346 |
| 2021-12-08 | Quigley Jill M. (Chief Operating Officer) | Option Ex | 71,975 | .23 | 16,554 |
| 2021-05-21 | Goldsmith Bruce A (CEO and President) | Buy | 2,000 | 13.12 | 26,230 |
| 2021-03-15 | Romano Gary (Chief Medical Officer) | Sale | 10,000 | 21.41 | 214,080 |
| 2021-03-15 | Romano Gary (Chief Medical Officer) | Option Ex | 10,000 | 8.07 | 80,700 |
| 2021-01-20 | Quigley Jill M. (Chief Operating Officer) | Sale | 1,300 | 30.01 | 39,011 |
| 2021-01-14 | Quigley Jill M. (Chief Operating Officer) | Sale | 16,298 | 30.10 | 490,569 |
| 2020-03-24 | Countouriotis Athena (Director) | Buy | 10,000 | 14.97 | 149,750 |
| 2020-03-03 | Fotopoulos Alexandros (Chief Technical Officer) | Buy | 5,500 | 18.00 | 99,000 |
| 2020-03-03 | Cale Edgar B. (GC and Corporate Secretary) | Buy | 2,000 | 18.00 | 36,000 |
| 2020-03-03 | Quigley Jill M. (Chief Operating Officer) | Buy | 2,500 | 18.00 | 45,000 |
| 2020-03-03 | Kapadia Sandip (Director) | Buy | 5,000 | 18.00 | 90,000 |
| 2020-03-03 | Woiwode Thomas (Director) | Buy | 450,000 | 18.00 | 8,100,000 |
| 2020-03-03 | Islam Saqib (Director) | Buy | 5,000 | 18.00 | 90,000 |
| 2020-03-03 | Countouriotis Athena (Director) | Buy | 8,900 | 18.00 | 160,200 |
| 2020-03-03 | Ratcliffe Liam (Director) | Buy | 2,800 | 18.00 | 50,400 |
| 2020-03-03 | Goldsmith Bruce A (CEO and President) | Buy | 1,100 | 18.00 | 19,800 |
| 2020-03-03 | Morris Richard Steven (Chief Financial Officer) | Buy | 400 | 18.00 | 7,200 |
| 2020-03-03 | Yamada Tadataka (Director) | Buy | 6,500 | 18.00 | 117,000 |
| 2020-03-03 | Heron Patrick J (Director) | Buy | 550,000 | 18.00 | 9,900,000 |
| 2020-03-03 | Topper James N (10% Owner) | Buy | 550,000 | 18.00 | 9,900,000 |
| 2020-02-28 | Orbimed Capital Gp Vii Llc (10% Owner) | Buy | 373,300 | 18.00 | 6,719,400 |
Insider trading activities including stock purchases, stock sales, and option exercises of PASG listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Passage Bio, Inc. (symbol PASG, CIK number 1787297) see the Securities and Exchange Commission (SEC) website.